Lorinda Chung, MD, MS - Recognizing and Managing Progressive Fibrosing ILD in Patients With Connective Tissue Diseases: Examining the Potential Clinical Implications of Antifibrotic Therapy

Go online to PeerView.com/ZBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung disease discuss the latest clinical evidence for the use of antifibrotic therapy for ILDs. Upon completion of this activity, participants should be better able to: Recognize the prevalence and risk of interstitial lung disease (ILD) in patients with connective tissue diseases (CTDs), including systemic sclerosis (SSc)-associated ILD, Identify signs, symptoms, and patterns of ILD with a progressive phenotype in patients with CTDs, including SSc-ILD, Review current management, including treatment and recommendations for monitoring, as well as the latest clinical evidence for the use of antifibrotic therapy for ILDs associated with a progressive phenotype such as SSc-ILD, Discuss the importance of a multidisciplinary approach that includes rheumatologists to the diagnosis and management of ILDs associated with CTDs